Evidence map›Paper›PMID 35854077›Full record

ArticlePharmaceutical research2022

Dextran Mass Ratio Controls Particle Drying Dynamics in a Thermally Stable Dry Powder Vaccine for Pulmonary Delivery.

Myla Manser, Blair A Morgan, Xueya Feng, Rod G Rhem, Myrna B Dolovich, Zhou Xing, Emily D Cranston, Michael R Thompson

Open access · bronzeAbstract read
In one paragraph

Article in Pharmaceutical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Myla ManserDepartment of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada.
Blair A MorganDepartment of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada.
Xueya FengMcMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada.
Rod G RhemFirestone Research Aerosol Laboratory, St. Joseph's Healthcare and Department of Medicine, McMaster University and Hamilton, Hamilton, ON, L8N 4A6, Canada.
Myrna B DolovichFirestone Research Aerosol Laboratory, St. Joseph's Healthcare and Department of Medicine, McMaster University and Hamilton, Hamilton, ON, L8N 4A6, Canada.
Zhou XingMcMaster Immunology Research Centre and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L7, Canada.
Emily D CranstonDepartment of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada.
Michael R ThompsonDepartment of Chemical Engineering, McMaster University, Hamilton, ON, L8S 4L7, Canada. mthomps@mcmaster.ca.
McMaster University · CAMcMaster University Medical Centre · CASt. Joseph’s Healthcare Hamilton · CA

Funding

CIHR 158260Natural Sciences and Engineering Research Council of Canada CHRP523837-18
6 · The paper itself

Abstract

purposeThermally stable, spray dried vaccines targeting respiratory diseases are promising candidates for pulmonary delivery, requiring careful excipient formulation to effectively encapsulate and protect labile biologics. This study investigates the impact of dextran mass ratio and molecular weight on activity retention, thermal stability and aerosol behaviour of a labile adenoviral vector (AdHu5) encapsulated within a spray dried mannitol-dextran blend.

methodsComparing formulations using 40 kDa or 500 kDa dextran at mass ratios of 1:3 and 3:1 mannitol to dextran, in vitro quantification of activity losses and powder flowability was used to assess suitability for inhalation.

resultsIncorporating mannitol in a 1:3 ratio with 500 kDa dextran reduced viral titre processing losses below 0.5 log and displayed strong thermal stability under accelerated aging conditions. Moisture absorption and agglomeration was higher in dextran-rich formulations, but under low humidity the 1:3 ratio with 500 kDa dextran powder had the lowest mass median aerodynamic diameter (4.4 µm) and 84% emitted dose from an intratracheal dosator, indicating strong aerosol performance.

conclusionsOverall, dextran-rich formulations increased viscosity during drying which slowed self-diffusion and favorably hindered viral partitioning at the particle surface. Reducing mannitol content also minimized AdHu5 exclusion from crystalline regions that can force the vector to air-solid interfaces where deactivation occurs. Although increased dextran molecular weight improved activity retention at the 1:3 ratio, it was less influential than the ratio parameter. Improving encapsulation ultimately allows inhalable vaccines to be prepared at higher potency, requiring less powder mass per inhaled dose and higher delivery efficiency.

Indexed as

ExcipientsVaccinesAdministration, InhalationAerosolsDextransDry Powder InhalersMannitolParticle SizePowdersAerosolsDextransExcipientsMannitolPowdersVaccinesDextranDrying dynamicsInhalationSpray dryingThermal stability

Identifiers

PMID35854077
PMCPMC9296218
OpenAlexW4286213443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.